Year 2016 / Volume 108 / Number 10
Original
How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey

618-626

DOI: 10.17235/reed.2016.4410/2016

Manuel Barreiro-de Acosta, Federico Argüelles-Arias, Joaquín Hinojosa, Francisco Javier Júdez Gutiérrez, Jose Maria Tenías Burillo,

Abstract
Introduction: Not all national health centers include specialized units or clinicians devoted to inflammatory bowel disease. The goal of the survey was to gain an insight into the management of this disease within Spanish gastroenterology departments via a survey among their members. Material and methods: An online survey was conducted in February and March 2015, among SEPD members (2017 clinician members), who were split into three categories: heads of department, general gastroenterologists, and experts in this disease. The results of the last two surveys are reported, including demography-related questions and specific questions on the strategies and resources available for the care of these patients. Results: A total of 166 responses were received (response rate 8.19%), excluding those from heads of department (previously published). Sixty gastroenterologists considered themselves experts in inflammatory bowel disease, and 106 non-experts in it, the latter being either general gastroenterologists or specialists in other areas, mainly endoscopy. Twenty-eight percent of non-expert gastroenterologists said their hospitals had specific units, with a monographic clinic in 46%. However, 26% reported that they were treating affected patients themselves. Experts in inflammatory bowel disease reported that their institute had resources to support their work, but there was a lack of surgeons with expertise in this condition, particularly in county hospitals. Conclusions: At least, within SEPD members, 2 out of 3 experts in inflammatory bowel disease seem to have the resources available for their work (nurses, day unit, telephone line, database, referrals, joint sessions). Although there is room for improvement (email to contact patients, devoted surgeon, absence of referral protocols), and 2 out of 3 are concerned about pharmacy costs. Since a substantial number of patients remain treated by general practitioners, rapid referral programs might be helpful in this setting.
Share Button
New comment
Comments

23/02/2017 21:18:54
Queridos colegas y amigos en la dura tarea del seguimiento de los enfermos que padecen una EII, me parece que vuestro trabajo pone de manifiesto la situación real de nuestra actividad, cuando hablamos de EII, lo que es de agradecer y vaya desde aquí mi felicitación por dicha labor. No obstante quisiera que considerarais la posibildad de que cuando hableis de especialistas de aparato digestivo no lo hagáis diciendo "los digestivos" creo que queda mucho mas correcto si se utilizan los términos Gastroenterólogos o especialistas de ap. digestivo o incluso digestólogos, no sé que os parece, pero a mi particularmente me chirría el término "los digestivos".
Un cordial saludo. Francisco Domínguez Abascal. Especialista de Aparato Digestivo


References
1. M'Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013; 6: 33-47. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/24833941
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1): 46-54.e42; quiz e30. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/22001864
3. Barreiro-de-Acosta M. The importance of the interaction between doctor and patient with inflammatory bowel disease. Rev Esp Enferm Dig. 2014; 106(6): 369-71. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/25361446
4. Mawdsley JE, Irving PM, Makins RJ, et al. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol. 2006; 18(3): 249-53. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/16462537
5. Mikocka-Walus AA, Andrews JM, Bernstein CN, et al. Integrated models of care in managing inflammatory bowel disease: a discussion. Inflamm Bowel Dis. 2012; 18(8): 1582-7. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/22241699
6. Argüelles-Arias F, Rodríguez Ledo P, Tenías JM, et al. The management of lactose intolerance among primary care physicians and its correlation with management by gastroenterologists: the SEPD-SEMG national survey. Rev Esp Enferm Dig. 2015; 107(9): 554-8. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/26334462
7. Argüelles-Arias F, Tenías JM, Casellas-Jordá F, et al. Results of a nation-wide survey on hypolactasia--how is this condition diagnosed and managed in our setting?Rev Esp Enferm Dig. 2015; 107(1): 55-6. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/25603339
8. Lucendo AJ, González-Huix F, Tenias JM, et al. Gastrointestinal endoscopy sedation and monitoring practices in Spain: a nationwide survey in the year 2014. Endoscopy. 2015; 47(4): 383-90. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/25826173
9. Argüelles Arias F, Barreiro-de Acosta M, Hinojosa J. Pharmaceutical costs for inflammatory bowel disease units - An issue for department heads? The GESTIONAEII survey. Rev Esp Enferm Dig. 2016; 108. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/26937746
10. Casellas F, Vera I, Ginard D, et al. Inflammatory bowel disease patient's satisfaction with healthcare services received. Physicians' and nurses' perceptions. Rev Esp Enferm Dig. 2013; 105(7): 385-91. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/24206548
11. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014; 8(11): 1548-50. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/25008477
12. Barreiro-de Acosta M, Magro F, Carpio D, et al. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflamm Bowel Dis. 2010; 16(7): 1227-38. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/19924807
13. Magro F, Barreiro-de Acosta M, Lago P, et al. Clinical practice in Crohn's disease in bordering regions of two countries: different medical options, distinct surgical events. J Crohns Colitis. 2010; 4(3): 301-11. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/21122519
14. Cabriada JL, Vera I, Domènech E, et al. [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol. 2013; 36(3): 127-46. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/23433780
15. Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014; 63(4): 588-97. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/23604131
16. Hernández-Sampelayo P, Seoane M, Oltra L, et al. Contribution of nurses to the quality of care in management of inflammatory bowel disease: a synthesis of the evidence. J Crohns Colitis. 2010; 4(6): 611-22. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/21122570
17. Ramos-Rivers C, Regueiro M, Vargas EJ, et al. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014; 12(6): 986-94.e1. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/24262938
18. Nguyen GC, Steinhart AH. The impact of surgeon volume on postoperative outcomes after surgery for Crohn's disease. Inflamm Bowel Dis. 2014; 20(2): 301-6. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/24374877
19. Calvet X, Panés J, Alfaro N, et al. Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis. 2014; 8(3): 240-51. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/24295646
20. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013; 19(3): 662-8. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/23388547
21. Bernstein CN, Longobardi T, Finlayson G, et al. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012; 18(8): 1498-508. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/22109958
22. Tang DH, Harrington AR, Lee JK, et al. A systematic review of economic studies on biological agents used to treat Crohn's disease. Inflamm Bowel Dis. 2013; 19(12): 2673-94. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/23792552
23. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way?Best Pract Res Clin Gastroenterol. 2014; 28(3): 465-71. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/24913385
24. Argüelles-Arias F, Barreiro-de-Acosta M, Carballo F, et al. Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig. 2013; 105(1): 37-43. Accesible en:http://www.ncbi.nlm.nih.gov/pubmed/23548008
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Barreiro-de Acosta M, Argüelles-Arias F, Hinojosa J, Júdez Gutiérrez F, Tenías Burillo J. How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey. 4410/2016


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 902 visits.
This article has been downloaded 243 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 24/04/2016

Accepted: 22/05/2016

Online First: 21/09/2016

Published: 30/09/2016

Article revision time: 23 days

Article Online First time: 150 days

Article editing time: 159 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology